Healthy Extracts Reports First Quarter 2024 Financial Results
Healthy Extracts (OTCQB:HYEX) reported first-quarter 2024 financial results. Net revenue rose 12% to $689,000, driven by distribution expansion and subscription revenue growth. Gross margin increased to 59.3% from 45.2%, thanks to improved manufacturing efficiency. The company achieved a positive cash flow of $68,000 for the second consecutive quarter.
Net loss was $861,000 or $(0.30) per share, primarily due to interest expenses and stock-based compensation. Excluding non-core costs, the net income was $2,500. Subscription growth was strong, with Amazon 'Subscribe & Save' customers up 81% and direct-to-consumer subscriptions up 28% year-over-year.
The company plans to launch new products in the latter half of 2024, including anti-aging and sugar blocker gel packs. Healthy Extracts aims for continued growth and profitability in upcoming quarters.
- Net revenue increased by 12% to $689,000.
- Gross margin improved to 59.3% from 45.2%.
- Achieved a second consecutive quarter of positive cash flow at $68,000.
- Amazon 'Subscribe & Save' customers grew by 81%.
- Direct-to-consumer subscriptions increased by 28%.
- Operating expenses decreased by $286,000 from the previous year.
- Completed a debt restructuring, adding $15,000 a month in positive cash flow.
- Net loss increased to $861,000 or $(0.30) per share.
- Net income, excluding non-core costs, was just $2,500.
- Interest expense, stock-based compensation, and change in fair value of derivatives negatively impacted net results.
Net Revenue up
LAS VEGAS, NV / ACCESSWIRE / May 20, 2024 / Healthy Extracts Inc. (OTCQB:HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported results for the quarter ended March 31, 2024. All comparisons are to the year-ago period unless otherwise noted.
Q1 2024 Financial Highlights
- Net revenue increased
12% to$689,000 , driven primarily by distribution channel expansion and growth in subscription-based revenue. - Gross margin expanded to
59.3% from45.2% due to improved manufacturing efficiency. - Achieved second sequential positive cash flow quarter, generating
$68,000 in the quarter. - Net loss of
$861,000 or$(0.30) per basic and diluted share, primarily due to interest expense, stock-based compensation and the change in fair value of derivatives. - Net totaled of
$2,500 after excluding non-core and non-cash costs associated with a planned acquisition and public offering expenses, regulatory expense, stock-based compensation, change in fair value of derivative expense, and interest expense. Excluding these costs, the first quarter of 2024 was the second quarter in a row of profitability. - Amazon "Subscribe & Save" customers at March 31, 2024 increased
81% versus March 31, 2023. Subscription growth helps reduce customer acquisition costs, increases traction, and provides greater visibility into future revenue. - Direct-to-consumer subscription customers at March 31, 2024 increased
28% versus March 31, 2023.
Management Commentary
"In Q1, our top line continued to grow at a healthy double-digit pace, as our product offerings, customer subscriptions, and distribution channels continued to develop and expand," commented Healthy Extracts president, Duke Pitts. "During the quarter, our enhanced manufacturing efficiencies expanded gross margins by 14.1 percentage points to
"These favorable trends contributed to our second cash flow positive quarter in a row at
"This performance has put us on a solid financial foundation in terms of cash flow and ability to service debt. At the beginning of April, we completed a restructuring and streamlining of debt which resulted in an additional
"Altogether, Healthy Extracts have never been in a stronger financial position, setting the stage for continued growth without increasing our dependence on the financings or the capital markets.
"Last week, we engaged Bush & Associates as our new independent registered public accounting firm. We believe their more favorable rate structure and nearby locality will decrease our accounting costs and improve efficiencies for future quarters.
"In the second half of this year, we plan to launch several new products into our diverse sales and distribution channels. The new products, which are far along in development, expand our proprietary and patented product portfolio into new categories. Introductions include our exclusive Gelteq delivery system in the anti-aging and sugar blockers categories. We expect their launch will benefit from the broad market channels and customer base we have strategically developed and invested in over the last several years.
"Our overall growth strategy continues to involve both organic growth and strategic acquisitions, with a razor-sharp focus on acquisition targets that experience new exponential growth by leveraging our extensive distribution systems and network.
"We continued our efforts to uplist to a major U.S. stock exchange which we believe would help strengthen our position to acquire complementary businesses.
"We anticipate continued strong progress through the rest of the year for Healthy Extracts, as we focus on top line growth, increased cash flow, and market share expansion."
2024 Financial Outlook
In Q2 and Q3, the company anticipates continued growth and profitability excluding non-cash transactions.
2024 Product Outlook
Healthy Extracts' top brand ambassador and renowned fitness expert, Whitney Johns, is preparing to launch WHITNEY JOHNS™ NUTRITION on-the-go gel packs for COLLAGEN (anti-aging) second half of 2024. These products will be based on Healthy Extracts' exclusive oral delivery system and proprietary formulations.
The company is also planning to launch in the second half of 2024 its new BergaMet MYNUS sugar blocker, which is specially formulated to reduce up to
Q1 2024 Financial Summary
Net revenue in the first quarter of 2024 increased
Gross profit totaled
Operating expenses, excluding the offering and regulatory expense, and stock compensation expense, decreased
Net loss totaled
Excluding costs related to the company's planned acquisition and public offering expenses, regulatory expense, stock-based compensation expense, change in fair value of derivative expense and interest expense, net income in the first quarter of 2024 totaled
About Healthy Extracts "Live Life Young Again"
Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals.
The company's subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids.
UBN's KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities.
For more information visit: healthyextractsinc.com , bergametna.com or tryubn.com .
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2024, and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Food & Drug Administration Disclosure
The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™
Company Contact
Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact
Investor Contact
Ronald Both
CMA Investor Relations
Tel (949) 432-7566
Email contact
Media Contact:
Tim Randall
CMA Media Relations
Tel (949) 432-7572
Email Contact
HEALTHY EXTRACTS, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE MONTH ENDING MARCH 31, 2024 AND 2023
(Unaudited)
| FOR THE MONTHS ENDING | ||||||||
| MARCH 31 | ||||||||
| 2024 | 2023 | |||||||
REVENUE | ||||||||
Revenue | $ | 688,786 | $ | 614,943 | ||||
Net revenue | 688,786 | 614,943 | ||||||
COST OF REVENUE | ||||||||
Cost of goods sold | 280,428 | 337,102 | ||||||
Total cost of revenue | 280,428 | 337,102 | ||||||
GROSS PROFIT | 408,358 | 277,841 | ||||||
OPERATING EXPENSES | ||||||||
General and administrative | 470,431 | 683,029 | ||||||
Total operating expenses | 470,431 | 683,029 | ||||||
OTHER INCOME (EXPENSE) | ||||||||
Interest expense, net of interest income | (42,557 | ) | (89,060 | ) | ||||
Change in fair value on derivative | (756,628 | ) | (84,908 | ) | ||||
Total other income (expense) | (799,185 | ) | (173,968 | ) | ||||
Net income/(loss) before income tax provision | (861,259 | ) | (579,157 | ) | ||||
NET INCOME/(LOSS) | $ | (861,259 | ) | $ | (579,157 | ) | ||
Income/(Loss) per share - basic and diluted | $ | (0.30 | ) | $ | (0.20 | ) | ||
Weighted average number of shares outstanding - basic and diluted | 2,915,410 | 2,854,290 | ||||||
HEALTHY EXTRACTS, INC.
CONSOLIDATED BALANCE SHEETS
AS OF MARCH 31, 2024 AND DECEMBER 31, 2023
(Unaudited)
| MARCH 31, | DECEMBER 31, | |||||||
| 2024 | 2023 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash | $ | 87,312 | $ | 19,441 | ||||
Accounts receivable | 24,055 | 30,440 | ||||||
Inventory, net | 1,552,814 | 1,626,283 | ||||||
Offering costs | 149,274 | 151,931 | ||||||
Right of use asset, net | 56,523 | 71,583 | ||||||
Total current assets | 1,869,978 | 1,899,678 | ||||||
Fixed assets | 2,757 | 3,306 | ||||||
Patents/Trademarks | 521,881 | 521,881 | ||||||
Deposit | 16,890 | 16,890 | ||||||
Goodwill | 193,260 | 193,260 | ||||||
Total other assets | 734,787 | 735,336 | ||||||
TOTAL ASSETS | $ | 2,604,765 | $ | 2,635,014 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
LIABILITIES | ||||||||
Accounts payable | $ | 117,515 | $ | 116,842 | ||||
Accrued liabilities | 206,452 | 215,069 | ||||||
Lease liabilities - current | 58,906 | 65,229 | ||||||
Lease liabilities - long-term | - | 9,222 | ||||||
Notes payable | 295,795 | 361,093 | ||||||
Notes payable - related party | 178,366 | 83,366 | ||||||
Convertible debt, net of discount | 628,045 | 608,601 | ||||||
Accrued interest payable | 50,647 | 64,386 | ||||||
Accrued interest payable - related party | 6,615 | 2,465 | ||||||
Derivative liabilities | 910,779 | 154,150 | ||||||
Total current and total liabilities | 2,453,120 | 1,680,424 | ||||||
STOCKHOLDERS' EQUITY | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | 354,502 | 354,492 | ||||||
Additional paid-in capital | 19,058,075 | 18,999,770 | ||||||
Accumulated deficit | (19,260,931 | ) | (18,399,673 | ) | ||||
Total stockholders' equity | 151,646 | 954,590 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 2,604,765 | $ | 2,635,014 | ||||
HEALTHY EXTRACTS, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited)
| FOR THE MONTH ENDING | ||||||||
| MARCH 31 | ||||||||
| 2024 | 2023 | |||||||
Cash Flows from Operating Activities: | ||||||||
Net Income/(Loss) | $ | (861,259 | ) | $ | (579,157 | ) | ||
Adjustments to reconcile net loss to net cash | ||||||||
used in operating activities: | ||||||||
Depreciation and amortization | 549 | 549 | ||||||
Warrants issued for services | 58,314 | 16,000 | ||||||
Change in fair value on derivative liability | 756,628 | 84,908 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 6,385 | (29,604 | ) | |||||
Inventory | 73,469 | 164,922 | ||||||
Offering Costs | 2,657 | - | ||||||
Cost in acquisition of Hyperion/OP&M | - | (32,617 | ) | |||||
Right of use asset, net | 15,060 | - | ||||||
Accounts payable | 673 | 23,170 | ||||||
Accrued liabilities | (8,617 | ) | (8,683 | ) | ||||
Accrued interest payable | (13,739 | ) | 17,636 | |||||
Accrued interest payable - related party | 4,150 | - | ||||||
Lease liability - current | (6,324 | ) | - | |||||
Lease liability - long-term | (9,222 | ) | - | |||||
Net Cash used in Operating Activities | 18,724 | (342,876 | ) | |||||
Cash Flows from Investing Activities: | ||||||||
Purchase of fixed assets | - | - | ||||||
Gain on sale of asset | - | - | ||||||
Cash flows provided by (used in) Investing Activities: | - | - | ||||||
Cash Flows from Financing Activities: | ||||||||
Proceeds from issuance of common stock | - | - | ||||||
Proceeds from issuance of convertible debt | 19,445 | 388,888 | ||||||
Payments for repayment of convertible debt | - | (110,535 | ) | |||||
Proceeds from issuance of notes payable | 118,132 | 136,705 | ||||||
Payments for repayment of notes payable | (183,430 | ) | 75,370 | |||||
Proceeds from issuance of notes payable - related party | 95,000 | - | ||||||
Payments for repayment of notes payable - related party | - | - | ||||||
Loan origination fees | - | - | ||||||
Net Cash provided by Financing Activities | 49,146 | 490,429 | ||||||
Increase (decrease) in cash | 67,871 | 147,553 | ||||||
Cash at beginning of period | 19,441 | 65,651 | ||||||
Cash at end of period | $ | 87,312 | $ | 213,204 | ||||
SOURCE: Healthy Extracts Inc.
View the original press release on accesswire.com
FAQ
What was Healthy Extracts' net revenue for Q1 2024?
What was Healthy Extracts' gross margin for Q1 2024?
What was Healthy Extracts' net loss in Q1 2024?
How much did Healthy Extracts' Amazon 'Subscribe & Save' customers grow?
What new products is Healthy Extracts planning to launch in 2024?
What was Healthy Extracts' cash flow for Q1 2024?
